Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: PAL who wrote (4221)	5/5/1998 12:34:00 PM
From: sam	Read Replies (1) of 6136

You're probably right. But Johnson was just on CNBC after AGPH released its numbers. The following is from Briefing.com: Agouron Pharmaceuticals Inc. (AGPH) 38 1/8 +3 3/4: integrated pharmaceutical company announces the initiation of phase II/III clinical trials, in patients with advanced lung or prostate cancer, to evaluate an experimental anticancer agent known as AG3340; in rodents, drug potently inhibits angiogenesis tumor growth and metastasis, while enhancing anti-tumor activity of certain conventional chemotherapy agents.....

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next